Protease 3C
rhinovirus B14
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein–RNA Heteromer Protein × 3 RNA 1 PDB declaration: tetrameric（4） Consistent with all polymer counts | Chain A； UniProt 1539–1718 | Not recorded | YDF heavy chain × 1 YDF light chain × 1 RNA (83-MER) × 1 | ELECTRON MICROSCOPY cryo-EM buffer：pH 8 cryo-EM vitrification conditions：Cryogen ETHANE | Resolution 3.17 Å |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 9WB3 | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1D3I CRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 14 (HRV14) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY Deposited 1999-09-29 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 300 PDB declaration: 300-MERIC |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
HRV14 WAS INCUBATED WITH D1D2-ICAM-1 FOR 30 MINUTES AT 4
DEGREES CELSIUS (277 KELVIN) USING AN EIGHT-FOLD EXCESS
OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING
SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED
AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR
LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE
WITH A GATAN 626 CRYOTRANSFER HOLDER.
|
Resolution 26.00 Å |
| 1D3I CRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 14 (HRV14) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY Deposited 1999-09-29 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
HRV14 WAS INCUBATED WITH D1D2-ICAM-1 FOR 30 MINUTES AT 4
DEGREES CELSIUS (277 KELVIN) USING AN EIGHT-FOLD EXCESS
OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING
SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED
AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR
LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE
WITH A GATAN 626 CRYOTRANSFER HOLDER.
|
Resolution 26.00 Å |
| 1D3I CRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 14 (HRV14) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY Deposited 1999-09-29 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 25 PDB declaration: 25-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
HRV14 WAS INCUBATED WITH D1D2-ICAM-1 FOR 30 MINUTES AT 4
DEGREES CELSIUS (277 KELVIN) USING AN EIGHT-FOLD EXCESS
OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING
SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED
AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR
LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE
WITH A GATAN 626 CRYOTRANSFER HOLDER.
|
Resolution 26.00 Å |
| 1D3I CRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 14 (HRV14) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY Deposited 1999-09-29 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 30 PDB declaration: 30-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
HRV14 WAS INCUBATED WITH D1D2-ICAM-1 FOR 30 MINUTES AT 4
DEGREES CELSIUS (277 KELVIN) USING AN EIGHT-FOLD EXCESS
OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING
SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED
AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR
LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE
WITH A GATAN 626 CRYOTRANSFER HOLDER.
|
Resolution 26.00 Å |
| 1D3I CRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 14 (HRV14) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY Deposited 1999-09-29 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
HRV14 WAS INCUBATED WITH D1D2-ICAM-1 FOR 30 MINUTES AT 4
DEGREES CELSIUS (277 KELVIN) USING AN EIGHT-FOLD EXCESS
OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING
SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED
AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR
LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE
WITH A GATAN 626 CRYOTRANSFER HOLDER.
|
Resolution 26.00 Å |
| 1HRI STRUCTURE DETERMINATION OF ANTIVIRAL COMPOUND SCH 38057 COMPLEXED WITH HUMAN RHINOVIRUS 14 Deposited 1992-10-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | S57 1-[6-(2-CHLORO-4-METHYXYPHENOXY)-HEXYL]-IMIDAZOLE × 60 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1HRI STRUCTURE DETERMINATION OF ANTIVIRAL COMPOUND SCH 38057 COMPLEXED WITH HUMAN RHINOVIRUS 14 Deposited 1992-10-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | S57 1-[6-(2-CHLORO-4-METHYXYPHENOXY)-HEXYL]-IMIDAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1HRI STRUCTURE DETERMINATION OF ANTIVIRAL COMPOUND SCH 38057 COMPLEXED WITH HUMAN RHINOVIRUS 14 Deposited 1992-10-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | S57 1-[6-(2-CHLORO-4-METHYXYPHENOXY)-HEXYL]-IMIDAZOLE × 5 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1HRI STRUCTURE DETERMINATION OF ANTIVIRAL COMPOUND SCH 38057 COMPLEXED WITH HUMAN RHINOVIRUS 14 Deposited 1992-10-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | S57 1-[6-(2-CHLORO-4-METHYXYPHENOXY)-HEXYL]-IMIDAZOLE × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1HRI STRUCTURE DETERMINATION OF ANTIVIRAL COMPOUND SCH 38057 COMPLEXED WITH HUMAN RHINOVIRUS 14 Deposited 1992-10-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | S57 1-[6-(2-CHLORO-4-METHYXYPHENOXY)-HEXYL]-IMIDAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1HRI STRUCTURE DETERMINATION OF ANTIVIRAL COMPOUND SCH 38057 COMPLEXED WITH HUMAN RHINOVIRUS 14 Deposited 1992-10-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | S57 1-[6-(2-CHLORO-4-METHYXYPHENOXY)-HEXYL]-IMIDAZOLE × 20 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1HRV HRV14/SDZ 35-682 COMPLEX Deposited 1995-03-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: complete icosahedral assembly |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | SDZ 1-[2-HYDROXY-3-(4-CYCLOHEXYL-PHENOXY)-PROPYL]-4-(2-PYRIDYL)-PIPERAZINE × 60 |
X-RAY DIFFRACTION
X-ray crystallization conditions
3-4 CRYSTALS SOAKED IN 200 MICROLITER DROPS OF SDZ 35-682
(5 MICROGRAM/ML).
|
Resolution 3.00 Å |
| 1HRV HRV14/SDZ 35-682 COMPLEX Deposited 1995-03-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | SDZ 1-[2-HYDROXY-3-(4-CYCLOHEXYL-PHENOXY)-PROPYL]-4-(2-PYRIDYL)-PIPERAZINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
3-4 CRYSTALS SOAKED IN 200 MICROLITER DROPS OF SDZ 35-682
(5 MICROGRAM/ML).
|
Resolution 3.00 Å |
| 1HRV HRV14/SDZ 35-682 COMPLEX Deposited 1995-03-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | SDZ 1-[2-HYDROXY-3-(4-CYCLOHEXYL-PHENOXY)-PROPYL]-4-(2-PYRIDYL)-PIPERAZINE × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
3-4 CRYSTALS SOAKED IN 200 MICROLITER DROPS OF SDZ 35-682
(5 MICROGRAM/ML).
|
Resolution 3.00 Å |
| 1HRV HRV14/SDZ 35-682 COMPLEX Deposited 1995-03-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | SDZ 1-[2-HYDROXY-3-(4-CYCLOHEXYL-PHENOXY)-PROPYL]-4-(2-PYRIDYL)-PIPERAZINE × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
3-4 CRYSTALS SOAKED IN 200 MICROLITER DROPS OF SDZ 35-682
(5 MICROGRAM/ML).
|
Resolution 3.00 Å |
| 1HRV HRV14/SDZ 35-682 COMPLEX Deposited 1995-03-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | SDZ 1-[2-HYDROXY-3-(4-CYCLOHEXYL-PHENOXY)-PROPYL]-4-(2-PYRIDYL)-PIPERAZINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
3-4 CRYSTALS SOAKED IN 200 MICROLITER DROPS OF SDZ 35-682
(5 MICROGRAM/ML).
|
Resolution 3.00 Å |
| 1HRV HRV14/SDZ 35-682 COMPLEX Deposited 1995-03-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | SDZ 1-[2-HYDROXY-3-(4-CYCLOHEXYL-PHENOXY)-PROPYL]-4-(2-PYRIDYL)-PIPERAZINE × 20 |
X-RAY DIFFRACTION
X-ray crystallization conditions
3-4 CRYSTALS SOAKED IN 200 MICROLITER DROPS OF SDZ 35-682
(5 MICROGRAM/ML).
|
Resolution 3.00 Å |
| 1K5M Crystal Structure of a Human Rhinovirus Type 14:Human Immunodeficiency Virus Type 1 V3 Loop Chimeric Virus MN-III-2 Deposited 2001-10-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 240 PDB declaration: 240-MERIC |
Chain A
568–856（289 aa）
Chain B
70–228（159 aa）
Chain B
229–331（103 aa）
Chain C
332–567（236 aa）
Chain D
2–69（68 aa）
|
Not recorded | SPH SPHINGOSINE × 60 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；1.5 M ammonium formate and 0.15 M sodium HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.70 Å |
| 1K5M Crystal Structure of a Human Rhinovirus Type 14:Human Immunodeficiency Virus Type 1 V3 Loop Chimeric Virus MN-III-2 Deposited 2001-10-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Insufficient information Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
568–856（289 aa）
Chain B
70–228（159 aa）
Chain B
229–331（103 aa）
Chain C
332–567（236 aa）
Chain D
2–69（68 aa）
|
Not recorded | SPH SPHINGOSINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；1.5 M ammonium formate and 0.15 M sodium HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.70 Å |
| 1K5M Crystal Structure of a Human Rhinovirus Type 14:Human Immunodeficiency Virus Type 1 V3 Loop Chimeric Virus MN-III-2 Deposited 2001-10-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Insufficient information Heteromer；Protein × 20 PDB declaration: eicosameric |
Chain A
568–856（289 aa）
Chain B
70–228（159 aa）
Chain B
229–331（103 aa）
Chain C
332–567（236 aa）
Chain D
2–69（68 aa）
|
Not recorded | SPH SPHINGOSINE × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；1.5 M ammonium formate and 0.15 M sodium HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.70 Å |
| 1K5M Crystal Structure of a Human Rhinovirus Type 14:Human Immunodeficiency Virus Type 1 V3 Loop Chimeric Virus MN-III-2 Deposited 2001-10-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Insufficient information Heteromer；Protein × 24 PDB declaration: 24-meric |
Chain A
568–856（289 aa）
Chain B
70–228（159 aa）
Chain B
229–331（103 aa）
Chain C
332–567（236 aa）
Chain D
2–69（68 aa）
|
Not recorded | SPH SPHINGOSINE × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；1.5 M ammonium formate and 0.15 M sodium HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.70 Å |
| 1K5M Crystal Structure of a Human Rhinovirus Type 14:Human Immunodeficiency Virus Type 1 V3 Loop Chimeric Virus MN-III-2 Deposited 2001-10-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Insufficient information Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
568–856（289 aa）
Chain B
70–228（159 aa）
Chain B
229–331（103 aa）
Chain C
332–567（236 aa）
Chain D
2–69（68 aa）
|
Not recorded | SPH SPHINGOSINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；1.5 M ammonium formate and 0.15 M sodium HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.70 Å |
| 1K5M Crystal Structure of a Human Rhinovirus Type 14:Human Immunodeficiency Virus Type 1 V3 Loop Chimeric Virus MN-III-2 Deposited 2001-10-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Insufficient information Heteromer；Protein × 60 PDB declaration: 60-meric |
Chain A
568–856（289 aa）
Chain B
70–228（159 aa）
Chain B
229–331（103 aa）
Chain C
332–567（236 aa）
Chain D
2–69（68 aa）
|
Not recorded | SPH SPHINGOSINE × 15 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；1.5 M ammonium formate and 0.15 M sodium HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.70 Å |
| 1NA1 The structure of HRV14 when complexed with Pleconaril Deposited 2002-11-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC |
Chain A
568–856（289 aa）
Chain B
70–331（262 aa）
Chain C
332–567（236 aa）
Chain D
2–69（68 aa）
|
Not recorded | W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 60 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；HEPES, NaCl, CaCl2, PEG8K, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 3.30 Å R-free 0.228 |
| 1NA1 The structure of HRV14 when complexed with Pleconaril Deposited 2002-11-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
568–856（289 aa）
Chain B
70–331（262 aa）
Chain C
332–567（236 aa）
Chain D
2–69（68 aa）
|
Not recorded | W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；HEPES, NaCl, CaCl2, PEG8K, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 3.30 Å R-free 0.228 |
| 1NA1 The structure of HRV14 when complexed with Pleconaril Deposited 2002-11-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain A
568–856（289 aa）
Chain B
70–331（262 aa）
Chain C
332–567（236 aa）
Chain D
2–69（68 aa）
|
Not recorded | W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；HEPES, NaCl, CaCl2, PEG8K, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 3.30 Å R-free 0.228 |
| 1NA1 The structure of HRV14 when complexed with Pleconaril Deposited 2002-11-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain A
568–856（289 aa）
Chain B
70–331（262 aa）
Chain C
332–567（236 aa）
Chain D
2–69（68 aa）
|
Not recorded | W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；HEPES, NaCl, CaCl2, PEG8K, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 3.30 Å R-free 0.228 |
| 1NA1 The structure of HRV14 when complexed with Pleconaril Deposited 2002-11-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
568–856（289 aa）
Chain B
70–331（262 aa）
Chain C
332–567（236 aa）
Chain D
2–69（68 aa）
|
Not recorded | W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；HEPES, NaCl, CaCl2, PEG8K, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 3.30 Å R-free 0.228 |
| 1NA1 The structure of HRV14 when complexed with Pleconaril Deposited 2002-11-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain A
568–856（289 aa）
Chain B
70–331（262 aa）
Chain C
332–567（236 aa）
Chain D
2–69（68 aa）
|
Not recorded | W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 20 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；HEPES, NaCl, CaCl2, PEG8K, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 3.30 Å R-free 0.228 |
| 1NCQ The structure of HRV14 when complexed with pleconaril, an antiviral compound Deposited 2002-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC |
Chain A
568–856（289 aa）
Chain B
70–331（262 aa）
Chain C
332–567（236 aa）
Chain D
2–69（68 aa）
|
Not recorded | W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 60 |
X-RAY DIFFRACTION
X-ray crystallization conditions
The crystal was soaked in stabilization buffer containing 2ug/ml pleconaril before data collection
|
Resolution 2.50 Å R-free 0.217 |
| 1NCQ The structure of HRV14 when complexed with pleconaril, an antiviral compound Deposited 2002-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
568–856（289 aa）
Chain B
70–331（262 aa）
Chain C
332–567（236 aa）
Chain D
2–69（68 aa）
|
Not recorded | W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
The crystal was soaked in stabilization buffer containing 2ug/ml pleconaril before data collection
|
Resolution 2.50 Å R-free 0.217 |
| 1NCQ The structure of HRV14 when complexed with pleconaril, an antiviral compound Deposited 2002-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain A
568–856（289 aa）
Chain B
70–331（262 aa）
Chain C
332–567（236 aa）
Chain D
2–69（68 aa）
|
Not recorded | W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
The crystal was soaked in stabilization buffer containing 2ug/ml pleconaril before data collection
|
Resolution 2.50 Å R-free 0.217 |
| 1NCQ The structure of HRV14 when complexed with pleconaril, an antiviral compound Deposited 2002-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain A
568–856（289 aa）
Chain B
70–331（262 aa）
Chain C
332–567（236 aa）
Chain D
2–69（68 aa）
|
Not recorded | W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
The crystal was soaked in stabilization buffer containing 2ug/ml pleconaril before data collection
|
Resolution 2.50 Å R-free 0.217 |
| 1NCQ The structure of HRV14 when complexed with pleconaril, an antiviral compound Deposited 2002-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
568–856（289 aa）
Chain B
70–331（262 aa）
Chain C
332–567（236 aa）
Chain D
2–69（68 aa）
|
Not recorded | W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
The crystal was soaked in stabilization buffer containing 2ug/ml pleconaril before data collection
|
Resolution 2.50 Å R-free 0.217 |
| 1NCQ The structure of HRV14 when complexed with pleconaril, an antiviral compound Deposited 2002-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain A
568–856（289 aa）
Chain B
70–331（262 aa）
Chain C
332–567（236 aa）
Chain D
2–69（68 aa）
|
Not recorded | W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 20 |
X-RAY DIFFRACTION
X-ray crystallization conditions
The crystal was soaked in stabilization buffer containing 2ug/ml pleconaril before data collection
|
Resolution 2.50 Å R-free 0.217 |
| 1R08 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W42 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-(HYDROXYETHYL OXYMETHYLENEOXYMETHYL) ISOXAZOLE × 60 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1R08 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W42 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-(HYDROXYETHYL OXYMETHYLENEOXYMETHYL) ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1R08 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W42 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-(HYDROXYETHYL OXYMETHYLENEOXYMETHYL) ISOXAZOLE × 5 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1R08 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W42 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-(HYDROXYETHYL OXYMETHYLENEOXYMETHYL) ISOXAZOLE × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1R08 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W42 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-(HYDROXYETHYL OXYMETHYLENEOXYMETHYL) ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1R08 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W42 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-(HYDROXYETHYL OXYMETHYLENEOXYMETHYL) ISOXAZOLE × 20 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1R09 HUMAN RHINOVIRUS 14 COMPLEXED WITH ANTIVIRAL COMPOUND R 61837 Deposited 1990-05-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | JEN 3-METHOXY-6-[4-(3-METHYLPHENYL)-1-PIPERAZINYL]PYRIDAZINE × 60 DMS DIMETHYL SULFOXIDE × 60 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1R09 HUMAN RHINOVIRUS 14 COMPLEXED WITH ANTIVIRAL COMPOUND R 61837 Deposited 1990-05-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | JEN 3-METHOXY-6-[4-(3-METHYLPHENYL)-1-PIPERAZINYL]PYRIDAZINE × 1 DMS DIMETHYL SULFOXIDE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1R09 HUMAN RHINOVIRUS 14 COMPLEXED WITH ANTIVIRAL COMPOUND R 61837 Deposited 1990-05-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | JEN 3-METHOXY-6-[4-(3-METHYLPHENYL)-1-PIPERAZINYL]PYRIDAZINE × 5 DMS DIMETHYL SULFOXIDE × 5 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1R09 HUMAN RHINOVIRUS 14 COMPLEXED WITH ANTIVIRAL COMPOUND R 61837 Deposited 1990-05-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | JEN 3-METHOXY-6-[4-(3-METHYLPHENYL)-1-PIPERAZINYL]PYRIDAZINE × 6 DMS DIMETHYL SULFOXIDE × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1R09 HUMAN RHINOVIRUS 14 COMPLEXED WITH ANTIVIRAL COMPOUND R 61837 Deposited 1990-05-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | JEN 3-METHOXY-6-[4-(3-METHYLPHENYL)-1-PIPERAZINYL]PYRIDAZINE × 1 DMS DIMETHYL SULFOXIDE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1R09 HUMAN RHINOVIRUS 14 COMPLEXED WITH ANTIVIRAL COMPOUND R 61837 Deposited 1990-05-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | JEN 3-METHOXY-6-[4-(3-METHYLPHENYL)-1-PIPERAZINYL]PYRIDAZINE × 20 DMS DIMETHYL SULFOXIDE × 20 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 60 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 5 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 20 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUC RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: complete icosahedral assembly |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 60 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.10 Å |
| 1RUC RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.10 Å |
| 1RUC RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 5 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.10 Å |
| 1RUC RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.10 Å |
| 1RUC RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.10 Å |
| 1RUC RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 20 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.10 Å |
| 1RUD RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: complete icosahedral assembly |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 60 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1RUD RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1RUD RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 5 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1RUD RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1RUD RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1RUD RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 20 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1RUE RHINOVIRUS 14 SITE DIRECTED MUTANT N1219A COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 60 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1RUE RHINOVIRUS 14 SITE DIRECTED MUTANT N1219A COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1RUE RHINOVIRUS 14 SITE DIRECTED MUTANT N1219A COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 5 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1RUE RHINOVIRUS 14 SITE DIRECTED MUTANT N1219A COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1RUE RHINOVIRUS 14 SITE DIRECTED MUTANT N1219A COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1RUE RHINOVIRUS 14 SITE DIRECTED MUTANT N1219A COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 20 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1RUF RHINOVIRUS 14 (HRV14) (MUTANT WITH ASN 1 219 REPLACED BY ALA (N219A IN CHAIN 1) Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: complete icosahedral assembly |
Chain 1
568–856（289 aa）
Chain 2
70–331（262 aa）
Chain 3
332–567（236 aa）
Chain 4
2–69（68 aa）
|
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1RUF RHINOVIRUS 14 (HRV14) (MUTANT WITH ASN 1 219 REPLACED BY ALA (N219A IN CHAIN 1) Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
568–856（289 aa）
Chain 2
70–331（262 aa）
Chain 3
332–567（236 aa）
Chain 4
2–69（68 aa）
|
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1RUF RHINOVIRUS 14 (HRV14) (MUTANT WITH ASN 1 219 REPLACED BY ALA (N219A IN CHAIN 1) Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
568–856（289 aa）
Chain 2
70–331（262 aa）
Chain 3
332–567（236 aa）
Chain 4
2–69（68 aa）
|
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1RUF RHINOVIRUS 14 (HRV14) (MUTANT WITH ASN 1 219 REPLACED BY ALA (N219A IN CHAIN 1) Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
568–856（289 aa）
Chain 2
70–331（262 aa）
Chain 3
332–567（236 aa）
Chain 4
2–69（68 aa）
|
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1RUF RHINOVIRUS 14 (HRV14) (MUTANT WITH ASN 1 219 REPLACED BY ALA (N219A IN CHAIN 1) Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
568–856（289 aa）
Chain 2
70–331（262 aa）
Chain 3
332–567（236 aa）
Chain 4
2–69（68 aa）
|
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1RUF RHINOVIRUS 14 (HRV14) (MUTANT WITH ASN 1 219 REPLACED BY ALA (N219A IN CHAIN 1) Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
568–856（289 aa）
Chain 2
70–331（262 aa）
Chain 3
332–567（236 aa）
Chain 4
2–69（68 aa）
|
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.90 Å |
| 1RUG RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: complete icosahedral assembly |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 60 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUG RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUG RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 5 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUG RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUG RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUG RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 20 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUH RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: complete icosahedral assembly |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 60 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUH RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUH RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 5 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUH RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUH RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUH RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 20 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUI RHINOVIRUS 14 MUTANT S1223G COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: complete icosahedral assembly |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 60 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUI RHINOVIRUS 14 MUTANT S1223G COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUI RHINOVIRUS 14 MUTANT S1223G COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 5 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUI RHINOVIRUS 14 MUTANT S1223G COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUI RHINOVIRUS 14 MUTANT S1223G COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUI RHINOVIRUS 14 MUTANT S1223G COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 20 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUJ RHINOVIRUS 14 MUTANT WITH SER 1 223 REPLACED BY GLY (S1223G) Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: complete icosahedral assembly |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUJ RHINOVIRUS 14 MUTANT WITH SER 1 223 REPLACED BY GLY (S1223G) Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUJ RHINOVIRUS 14 MUTANT WITH SER 1 223 REPLACED BY GLY (S1223G) Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUJ RHINOVIRUS 14 MUTANT WITH SER 1 223 REPLACED BY GLY (S1223G) Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUJ RHINOVIRUS 14 MUTANT WITH SER 1 223 REPLACED BY GLY (S1223G) Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RUJ RHINOVIRUS 14 MUTANT WITH SER 1 223 REPLACED BY GLY (S1223G) Deposited 1995-06-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 1RVF FAB COMPLEXED WITH INTACT HUMAN RHINOVIRUS Deposited 1996-09-05 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 360 PDB declaration: 360-MERIC |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 4.00 Å |
| 1RVF FAB COMPLEXED WITH INTACT HUMAN RHINOVIRUS Deposited 1996-09-05 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 4.00 Å |
| 1RVF FAB COMPLEXED WITH INTACT HUMAN RHINOVIRUS Deposited 1996-09-05 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 30 PDB declaration: 30-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 4.00 Å |
| 1RVF FAB COMPLEXED WITH INTACT HUMAN RHINOVIRUS Deposited 1996-09-05 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 36 PDB declaration: 36-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 4.00 Å |
| 1RVF FAB COMPLEXED WITH INTACT HUMAN RHINOVIRUS Deposited 1996-09-05 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 4.00 Å |
| 1RVF FAB COMPLEXED WITH INTACT HUMAN RHINOVIRUS Deposited 1996-09-05 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein heterocomplex Heteromer；Protein × 120 PDB declaration: 120-MERIC |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 4.00 Å |
| 1VRH HRV14/SDZ 880-061 COMPLEX Deposited 1996-02-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: complete icosahedral assembly |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L | SD8 2-[4-(2H-1,4-BENZOTHIAZINE-3-YL)-PIPERAZINE-1-LY]-1,3-THIAZOLE-4-CARBOXYLIC ACID ETHYLESTER × 60 |
X-RAY DIFFRACTION
X-ray crystallization conditions
5 MG/ML OF SDZ 880-061 IN 200 MICROLITER DROPS FOR 3 - 4 CRYSTALS
|
Resolution 3.00 Å |
| 1VRH HRV14/SDZ 880-061 COMPLEX Deposited 1996-02-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L | SD8 2-[4-(2H-1,4-BENZOTHIAZINE-3-YL)-PIPERAZINE-1-LY]-1,3-THIAZOLE-4-CARBOXYLIC ACID ETHYLESTER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
5 MG/ML OF SDZ 880-061 IN 200 MICROLITER DROPS FOR 3 - 4 CRYSTALS
|
Resolution 3.00 Å |
| 1VRH HRV14/SDZ 880-061 COMPLEX Deposited 1996-02-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L | SD8 2-[4-(2H-1,4-BENZOTHIAZINE-3-YL)-PIPERAZINE-1-LY]-1,3-THIAZOLE-4-CARBOXYLIC ACID ETHYLESTER × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
5 MG/ML OF SDZ 880-061 IN 200 MICROLITER DROPS FOR 3 - 4 CRYSTALS
|
Resolution 3.00 Å |
| 1VRH HRV14/SDZ 880-061 COMPLEX Deposited 1996-02-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L | SD8 2-[4-(2H-1,4-BENZOTHIAZINE-3-YL)-PIPERAZINE-1-LY]-1,3-THIAZOLE-4-CARBOXYLIC ACID ETHYLESTER × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
5 MG/ML OF SDZ 880-061 IN 200 MICROLITER DROPS FOR 3 - 4 CRYSTALS
|
Resolution 3.00 Å |
| 1VRH HRV14/SDZ 880-061 COMPLEX Deposited 1996-02-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L | SD8 2-[4-(2H-1,4-BENZOTHIAZINE-3-YL)-PIPERAZINE-1-LY]-1,3-THIAZOLE-4-CARBOXYLIC ACID ETHYLESTER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
5 MG/ML OF SDZ 880-061 IN 200 MICROLITER DROPS FOR 3 - 4 CRYSTALS
|
Resolution 3.00 Å |
| 1VRH HRV14/SDZ 880-061 COMPLEX Deposited 1996-02-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L | SD8 2-[4-(2H-1,4-BENZOTHIAZINE-3-YL)-PIPERAZINE-1-LY]-1,3-THIAZOLE-4-CARBOXYLIC ACID ETHYLESTER × 20 |
X-RAY DIFFRACTION
X-ray crystallization conditions
5 MG/ML OF SDZ 880-061 IN 200 MICROLITER DROPS FOR 3 - 4 CRYSTALS
|
Resolution 3.00 Å |
| 1XR5 Crystal Structure of the RNA-dependent RNA Polymerase 3D from human rhinovirus serotype 14 Deposited 2004-10-13 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1720–2179（460 aa）
Fragment：RNA-DIRECTED RNA POLYMERASE
|
Not recorded | SM SAMARIUM (III) ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；286 K；sodium formate, glycerol, pH 7.00, VAPOR DIFFUSION, HANGING DROP, temperature 286K
|
Resolution 2.80 Å R-free 0.293 |
| 2B0F NMR Structure of the Human Rhinovirus 3C Protease (serotype 14) with covalently bound Ace-LEALFQ-ethylpropionate inhibitor Deposited 2005-09-13 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1538–1719（182 aa）
Fragment：Human Rhinovirus serotype 14 3C Protease
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 6.5；25 K；Ionic strength (raw mmCIF value) 20mM KH2PO4；Pressure ambient
NMR measurement conditions
pH 6.5；25 K；Ionic strength (raw mmCIF value) 20mM KH2PO4；Pressure ambient
NMR sample composition
0.75mM HRV14-3C with covalent inhibitor
20mM KH2PO4
15mM DTT
0.5mM EDTA
0.1mM DSS
pH 6.5; 90% H2O, 10% D2O | 90% H2O/10% D2O
NMR sample composition
0.75mM HRV14-3C with covalent inhibitor
20mM KH2PO4
15mM DTT
0.5mM EDTA
0.1mM DSS
pD 6.5; 99.96% D2O | 99.96% D2O
|
Resolution not provided |
| 2HWB A comparison of the anti-rhinoviral drug binding pocket in hrv14 and hrv1a Deposited 1994-01-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W91 5-(3-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PROPYL)-3-METHYL ISOXAZOLE × 60 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2HWB A comparison of the anti-rhinoviral drug binding pocket in hrv14 and hrv1a Deposited 1994-01-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W91 5-(3-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PROPYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2HWB A comparison of the anti-rhinoviral drug binding pocket in hrv14 and hrv1a Deposited 1994-01-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W91 5-(3-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PROPYL)-3-METHYL ISOXAZOLE × 5 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2HWB A comparison of the anti-rhinoviral drug binding pocket in hrv14 and hrv1a Deposited 1994-01-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W91 5-(3-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PROPYL)-3-METHYL ISOXAZOLE × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2HWB A comparison of the anti-rhinoviral drug binding pocket in hrv14 and hrv1a Deposited 1994-01-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W91 5-(3-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PROPYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2HWB A comparison of the anti-rhinoviral drug binding pocket in hrv14 and hrv1a Deposited 1994-01-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W91 5-(3-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PROPYL)-3-METHYL ISOXAZOLE × 20 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2HWC A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A Deposited 1994-01-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W54 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 60 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2HWC A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A Deposited 1994-01-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W54 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2HWC A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A Deposited 1994-01-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W54 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 5 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2HWC A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A Deposited 1994-01-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W54 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2HWC A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A Deposited 1994-01-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W54 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2HWC A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A Deposited 1994-01-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W54 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 20 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2IN2 NMR Structure of the Apo Human Rhinovirus 3C Protease (serotype 14) Deposited 2006-10-05 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1537–1718（182 aa）
Fragment：Human Rhinovirus 3C Protease
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 6.5；298 K；Ionic strength (raw mmCIF value) 20 mM；Pressure 1
NMR sample composition
U-13C/15N; 20mM phosphate buffer; 0.5mM EDTA; 15mM DTT; 0.3% NaN3; 90% H2O, 10% D2O | 90% H2O/10% D2O
NMR sample composition
U-13C/15N; 20mM phosphate buffer; 0.5mM EDTA; 15mM DTT; NaN3; 99.6% D2O | 99.6% D2O
NMR sample composition
U-15N; 20mM phosphate buffer; 0.5mM EDTA; 15mM DTT; 90% H2O, 10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2R04 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W71 5-(7-(4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 60 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2R04 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W71 5-(7-(4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2R04 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W71 5-(7-(4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 5 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2R04 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W71 5-(7-(4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2R04 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W71 5-(7-(4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2R04 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W71 5-(7-(4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 20 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2R06 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 60 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2R06 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2R06 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 5 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2R06 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2R06 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2R06 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 20 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2R07 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W33 5-(5-(6-CHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 60 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2R07 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W33 5-(5-(6-CHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2R07 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W33 5-(5-(6-CHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 5 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2R07 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W33 5-(5-(6-CHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2R07 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W33 5-(5-(6-CHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2R07 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W33 5-(5-(6-CHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 20 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RM2 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W43 5-(7-(6-CHLORO-4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 60 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RM2 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W43 5-(7-(6-CHLORO-4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RM2 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W43 5-(7-(6-CHLORO-4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 5 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RM2 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W43 5-(7-(6-CHLORO-4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RM2 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W43 5-(7-(6-CHLORO-4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RM2 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W43 5-(7-(6-CHLORO-4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 20 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RR1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W8R 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 60 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RR1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W8R 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RR1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W8R 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 5 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RR1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W8R 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RR1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W8R 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RR1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W8R 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 20 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RS1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 60 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RS1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RS1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 5 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RS1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RS1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RS1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 20 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RS3 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W59 5-(7-(5-HYDRO-4-ETHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 60 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RS3 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W59 5-(7-(5-HYDRO-4-ETHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RS3 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W59 5-(7-(5-HYDRO-4-ETHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 5 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RS3 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W59 5-(7-(5-HYDRO-4-ETHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RS3 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W59 5-(7-(5-HYDRO-4-ETHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RS3 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W59 5-(7-(5-HYDRO-4-ETHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 20 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RS5 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W56 5-(5-(4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 60 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RS5 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W56 5-(5-(4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RS5 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W56 5-(5-(4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 5 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RS5 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W56 5-(5-(4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RS5 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W56 5-(5-(4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 2RS5 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | W56 5-(5-(4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 20 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 4PDW A benzonitrile analogue inhibits rhinovirus replication Deposited 2014-04-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 240 PDB declaration: 240-meric |
Chain A
568–856（289 aa）
Fragment：resdiues 568-856
Chain B
70–331（262 aa）
Fragment：resdiues 70-331
Chain C
332–567（236 aa）
Fragment：resdiues 332-657
|
Not recorded | GOL GLYCEROL × 240 2XK 4-[(4,5-dimethoxy-2-nitrophenyl)acetyl]benzonitrile × 60 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.2；293.15 K；PEG 8000, calcium chloride
|
Resolution 3.00 Å R-free 0.200 |
| 4PDW A benzonitrile analogue inhibits rhinovirus replication Deposited 2014-04-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
568–856（289 aa）
Fragment：resdiues 568-856
Chain B
70–331（262 aa）
Fragment：resdiues 70-331
Chain C
332–567（236 aa）
Fragment：resdiues 332-657
|
Not recorded | GOL GLYCEROL × 4 2XK 4-[(4,5-dimethoxy-2-nitrophenyl)acetyl]benzonitrile × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.2；293.15 K；PEG 8000, calcium chloride
|
Resolution 3.00 Å R-free 0.200 |
| 4PDW A benzonitrile analogue inhibits rhinovirus replication Deposited 2014-04-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 20 PDB declaration: eicosameric |
Chain A
568–856（289 aa）
Fragment：resdiues 568-856
Chain B
70–331（262 aa）
Fragment：resdiues 70-331
Chain C
332–567（236 aa）
Fragment：resdiues 332-657
|
Not recorded | GOL GLYCEROL × 20 2XK 4-[(4,5-dimethoxy-2-nitrophenyl)acetyl]benzonitrile × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.2；293.15 K；PEG 8000, calcium chloride
|
Resolution 3.00 Å R-free 0.200 |
| 4PDW A benzonitrile analogue inhibits rhinovirus replication Deposited 2014-04-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 24 PDB declaration: 24-meric |
Chain A
568–856（289 aa）
Fragment：resdiues 568-856
Chain B
70–331（262 aa）
Fragment：resdiues 70-331
Chain C
332–567（236 aa）
Fragment：resdiues 332-657
|
Not recorded | GOL GLYCEROL × 24 2XK 4-[(4,5-dimethoxy-2-nitrophenyl)acetyl]benzonitrile × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.2；293.15 K；PEG 8000, calcium chloride
|
Resolution 3.00 Å R-free 0.200 |
| 4PDW A benzonitrile analogue inhibits rhinovirus replication Deposited 2014-04-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
568–856（289 aa）
Fragment：resdiues 568-856
Chain B
70–331（262 aa）
Fragment：resdiues 70-331
Chain C
332–567（236 aa）
Fragment：resdiues 332-657
|
Not recorded | GOL GLYCEROL × 4 2XK 4-[(4,5-dimethoxy-2-nitrophenyl)acetyl]benzonitrile × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.2；293.15 K；PEG 8000, calcium chloride
|
Resolution 3.00 Å R-free 0.200 |
| 4RHV THE USE OF MOLECULAR-REPLACEMENT PHASES FOR THE REFINEMENT OF THE HUMAN RHINOVIRUS 14 STRUCTURE Deposited 1988-01-25 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 4RHV THE USE OF MOLECULAR-REPLACEMENT PHASES FOR THE REFINEMENT OF THE HUMAN RHINOVIRUS 14 STRUCTURE Deposited 1988-01-25 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 4RHV THE USE OF MOLECULAR-REPLACEMENT PHASES FOR THE REFINEMENT OF THE HUMAN RHINOVIRUS 14 STRUCTURE Deposited 1988-01-25 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 4RHV THE USE OF MOLECULAR-REPLACEMENT PHASES FOR THE REFINEMENT OF THE HUMAN RHINOVIRUS 14 STRUCTURE Deposited 1988-01-25 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 4RHV THE USE OF MOLECULAR-REPLACEMENT PHASES FOR THE REFINEMENT OF THE HUMAN RHINOVIRUS 14 STRUCTURE Deposited 1988-01-25 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 4RHV THE USE OF MOLECULAR-REPLACEMENT PHASES FOR THE REFINEMENT OF THE HUMAN RHINOVIRUS 14 STRUCTURE Deposited 1988-01-25 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric |
Chain 1
567–855（289 aa）
Chain 2
69–330（262 aa）
Chain 3
331–566（236 aa）
Chain 4
1–68（68 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.00 Å |
| 5W3E CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, full particle) Deposited 2017-06-07 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 360 PDB declaration: 360-meric |
Chain A
568–856（289 aa）
Fragment：UNP residues 568-856
Chain B
332–567（236 aa）
Fragment：UNP residues 332-567
Chain C
70–331（262 aa）
Fragment：UNP residues 70-331
Chain D
2–69（68 aa）
Fragment：UNP residues 2-69
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.53 Å |
| 5W3E CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, full particle) Deposited 2017-06-07 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
568–856（289 aa）
Fragment：UNP residues 568-856
Chain B
332–567（236 aa）
Fragment：UNP residues 332-567
Chain C
70–331（262 aa）
Fragment：UNP residues 70-331
Chain D
2–69（68 aa）
Fragment：UNP residues 2-69
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.53 Å |
| 5W3E CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, full particle) Deposited 2017-06-07 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 30 PDB declaration: 30-meric |
Chain A
568–856（289 aa）
Fragment：UNP residues 568-856
Chain B
332–567（236 aa）
Fragment：UNP residues 332-567
Chain C
70–331（262 aa）
Fragment：UNP residues 70-331
Chain D
2–69（68 aa）
Fragment：UNP residues 2-69
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.53 Å |
| 5W3E CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, full particle) Deposited 2017-06-07 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 36 PDB declaration: 36-meric |
Chain A
568–856（289 aa）
Fragment：UNP residues 568-856
Chain B
332–567（236 aa）
Fragment：UNP residues 332-567
Chain C
70–331（262 aa）
Fragment：UNP residues 70-331
Chain D
2–69（68 aa）
Fragment：UNP residues 2-69
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.53 Å |
| 5W3E CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, full particle) Deposited 2017-06-07 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
568–856（289 aa）
Fragment：UNP residues 568-856
Chain B
332–567（236 aa）
Fragment：UNP residues 332-567
Chain C
70–331（262 aa）
Fragment：UNP residues 70-331
Chain D
2–69（68 aa）
Fragment：UNP residues 2-69
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.53 Å |
| 5W3L CryoEM structure of rhinovirus B14 in complex with C5 Fab (4 degrees Celsius, molar ratio 1:3, full particle) Deposited 2017-06-08 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 360 PDB declaration: 360-meric |
Chain A
568–856（289 aa）
Fragment：UNP residues 568-856
Chain B
332–567（236 aa）
Fragment：UNP residues 332-567
Chain C
70–331（262 aa）
Fragment：UNP residues 70-331
Chain D
2–69（68 aa）
Fragment：UNP residues 2-69
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.71 Å |
| 5W3L CryoEM structure of rhinovirus B14 in complex with C5 Fab (4 degrees Celsius, molar ratio 1:3, full particle) Deposited 2017-06-08 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
568–856（289 aa）
Fragment：UNP residues 568-856
Chain B
332–567（236 aa）
Fragment：UNP residues 332-567
Chain C
70–331（262 aa）
Fragment：UNP residues 70-331
Chain D
2–69（68 aa）
Fragment：UNP residues 2-69
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.71 Å |
| 5W3L CryoEM structure of rhinovirus B14 in complex with C5 Fab (4 degrees Celsius, molar ratio 1:3, full particle) Deposited 2017-06-08 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 30 PDB declaration: 30-meric |
Chain A
568–856（289 aa）
Fragment：UNP residues 568-856
Chain B
332–567（236 aa）
Fragment：UNP residues 332-567
Chain C
70–331（262 aa）
Fragment：UNP residues 70-331
Chain D
2–69（68 aa）
Fragment：UNP residues 2-69
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.71 Å |
| 5W3L CryoEM structure of rhinovirus B14 in complex with C5 Fab (4 degrees Celsius, molar ratio 1:3, full particle) Deposited 2017-06-08 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 36 PDB declaration: 36-meric |
Chain A
568–856（289 aa）
Fragment：UNP residues 568-856
Chain B
332–567（236 aa）
Fragment：UNP residues 332-567
Chain C
70–331（262 aa）
Fragment：UNP residues 70-331
Chain D
2–69（68 aa）
Fragment：UNP residues 2-69
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.71 Å |
| 5W3L CryoEM structure of rhinovirus B14 in complex with C5 Fab (4 degrees Celsius, molar ratio 1:3, full particle) Deposited 2017-06-08 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
568–856（289 aa）
Fragment：UNP residues 568-856
Chain B
332–567（236 aa）
Fragment：UNP residues 332-567
Chain C
70–331（262 aa）
Fragment：UNP residues 70-331
Chain D
2–69（68 aa）
Fragment：UNP residues 2-69
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.71 Å |
| 5W3M CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:1, full particle) Deposited 2017-06-08 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 360 PDB declaration: 360-meric |
Chain A
568–856（289 aa）
Fragment：UNP residues 568-856
Chain B
332–567（236 aa）
Fragment：UNP residues 332-567
Chain C
70–331（262 aa）
Fragment：UNP residues 70-331
Chain D
2–69（68 aa）
Fragment：UNP residues 2-69
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.26 Å |
| 5W3M CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:1, full particle) Deposited 2017-06-08 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
568–856（289 aa）
Fragment：UNP residues 568-856
Chain B
332–567（236 aa）
Fragment：UNP residues 332-567
Chain C
70–331（262 aa）
Fragment：UNP residues 70-331
Chain D
2–69（68 aa）
Fragment：UNP residues 2-69
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.26 Å |
| 5W3M CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:1, full particle) Deposited 2017-06-08 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 30 PDB declaration: 30-meric |
Chain A
568–856（289 aa）
Fragment：UNP residues 568-856
Chain B
332–567（236 aa）
Fragment：UNP residues 332-567
Chain C
70–331（262 aa）
Fragment：UNP residues 70-331
Chain D
2–69（68 aa）
Fragment：UNP residues 2-69
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.26 Å |
| 5W3M CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:1, full particle) Deposited 2017-06-08 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 36 PDB declaration: 36-meric |
Chain A
568–856（289 aa）
Fragment：UNP residues 568-856
Chain B
332–567（236 aa）
Fragment：UNP residues 332-567
Chain C
70–331（262 aa）
Fragment：UNP residues 70-331
Chain D
2–69（68 aa）
Fragment：UNP residues 2-69
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.26 Å |
| 5W3M CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:1, full particle) Deposited 2017-06-08 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
568–856（289 aa）
Fragment：UNP residues 568-856
Chain B
332–567（236 aa）
Fragment：UNP residues 332-567
Chain C
70–331（262 aa）
Fragment：UNP residues 70-331
Chain D
2–69（68 aa）
Fragment：UNP residues 2-69
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.26 Å |
| 5W3O CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, empty particle) Deposited 2017-06-08 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 300 PDB declaration: 300-meric |
Chain A
568–856（289 aa）
Fragment：UNP residues 568-856
Chain B
332–567（236 aa）
Fragment：UNP residues 332-567
Chain C
70–331（262 aa）
Fragment：UNP residues 70-331
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.01 Å |
| 5W3O CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, empty particle) Deposited 2017-06-08 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
568–856（289 aa）
Fragment：UNP residues 568-856
Chain B
332–567（236 aa）
Fragment：UNP residues 332-567
Chain C
70–331（262 aa）
Fragment：UNP residues 70-331
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.01 Å |
| 5W3O CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, empty particle) Deposited 2017-06-08 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 25 PDB declaration: 25-meric |
Chain A
568–856（289 aa）
Fragment：UNP residues 568-856
Chain B
332–567（236 aa）
Fragment：UNP residues 332-567
Chain C
70–331（262 aa）
Fragment：UNP residues 70-331
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.01 Å |
| 5W3O CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, empty particle) Deposited 2017-06-08 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 30 PDB declaration: 30-meric |
Chain A
568–856（289 aa）
Fragment：UNP residues 568-856
Chain B
332–567（236 aa）
Fragment：UNP residues 332-567
Chain C
70–331（262 aa）
Fragment：UNP residues 70-331
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.01 Å |
| 5W3O CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, empty particle) Deposited 2017-06-08 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
568–856（289 aa）
Fragment：UNP residues 568-856
Chain B
332–567（236 aa）
Fragment：UNP residues 332-567
Chain C
70–331（262 aa）
Fragment：UNP residues 70-331
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.01 Å |
| 6HLT Crystal structure of human ACBD3 GOLD domain in complex with 3A protein of rhinovirus-14 (HRV14) Deposited 2018-09-11 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
1430–1485（56 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；10% w/v PEG 8000, 20% v/v ethylene glycol, 30 mM MgCl2, 30 mM CaCl2, 100 mM bicine/Tris pH 8.5
|
Resolution 2.81 Å R-free 0.239 |
| 6HLT Crystal structure of human ACBD3 GOLD domain in complex with 3A protein of rhinovirus-14 (HRV14) Deposited 2018-09-11 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
1430–1485（56 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；10% w/v PEG 8000, 20% v/v ethylene glycol, 30 mM MgCl2, 30 mM CaCl2, 100 mM bicine/Tris pH 8.5
|
Resolution 2.81 Å R-free 0.239 |
| 6KYZ HRV14 3C in complex with single chain antibody YDF Deposited 2019-09-20 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
1538–1719（182 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；0.1 M citrate
40% PEG600
|
Resolution 1.84 Å R-free 0.208 |
| 6KYZ HRV14 3C in complex with single chain antibody YDF Deposited 2019-09-20 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain D
1538–1719（182 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；0.1 M citrate
40% PEG600
|
Resolution 1.84 Å R-free 0.208 |
| 6KZ0 HRV14 3C in complex with single chain antibody GGVV Deposited 2019-09-21 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
1538–1719（182 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.6；293 K；0.1 M Tris-HCl,
25% MPEG5000,
0.2 M Li2SO4
|
Resolution 2.40 Å R-free 0.223 |
| 6KZ0 HRV14 3C in complex with single chain antibody GGVV Deposited 2019-09-21 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain D
1538–1719（182 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.6；293 K；0.1 M Tris-HCl,
25% MPEG5000,
0.2 M Li2SO4
|
Resolution 2.40 Å R-free 0.223 |
| 6KZ0 HRV14 3C in complex with single chain antibody GGVV Deposited 2019-09-21 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain G
1538–1719（182 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.6；293 K；0.1 M Tris-HCl,
25% MPEG5000,
0.2 M Li2SO4
|
Resolution 2.40 Å R-free 0.223 |
| 6KZ0 HRV14 3C in complex with single chain antibody GGVV Deposited 2019-09-21 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain J
1538–1719（182 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.6；293 K；0.1 M Tris-HCl,
25% MPEG5000,
0.2 M Li2SO4
|
Resolution 2.40 Å R-free 0.223 |
| 7BG6 HRV14 native particle solved by cryoEM Deposited 2021-01-06 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–RNA Homooligomer；Protein × 240 PDB declaration: 300-meric |
Chain 1
584–856（273 aa）
Chain 2
70–331（262 aa）
Chain 3
332–567（236 aa）
Chain 4
2–69（68 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4；PBS with ph = 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.60 Å |
| 7BG7 HRV14 in complex with its receptor ICAM-1 Deposited 2021-01-06 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 300 PDB declaration: 300-meric |
Chain 1
564–856（293 aa）
Chain 2
70–331（262 aa）
Chain 3
332–567（236 aa）
Chain 4
2–69（68 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4；PBS
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.40 Å |
| 7NUL Rhinovirus-14 ICAM-1 activated particle at pH 6.2 Deposited 2021-03-12 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 180 PDB declaration: 300-meric |
Chain 1
564–856（293 aa）
Chain 2
70–331（262 aa）
Chain 3
332–563（232 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 6.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.00 Å |
| 7NUM Rhinovirus-14 ICAM-1 empty particle at pH 6.2 Deposited 2021-03-12 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 180 PDB declaration: 300-meric |
Chain 1
564–856（293 aa）
Chain 2
70–331（262 aa）
Chain 3
332–563（232 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 6.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.90 Å |
| 7NUN Rhinovirus 14 ICAM-1 virion-like particle at pH 6.2 Deposited 2021-03-12 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–RNA Homooligomer；Protein × 240 PDB declaration: 300-meric |
Chain 1
564–856（293 aa）
Chain 2
70–331（262 aa）
Chain 3
332–567（236 aa）
Chain 4
2–69（68 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 6.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.60 Å |
| 7NUO Rhinovirus 14 empty particle at pH 6.2 Deposited 2021-03-12 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 180 PDB declaration: 300-meric |
Chain 1
564–856（293 aa）
Chain 2
70–331（262 aa）
Chain 3
332–563（232 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 6.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.90 Å |
| 7NUQ Rhinovirus 14 virion-like at pH 6.2 Deposited 2021-03-12 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–RNA Homooligomer；Protein × 240 PDB declaration: 300-meric |
Chain 1
564–856（293 aa）
Chain 2
70–331（262 aa）
Chain 3
332–567（236 aa）
Chain 4
2–69（68 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 6.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.80 Å |
| 8PNB HRV empty capsid Deposited 2023-06-30 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 180 PDB declaration: trimeric |
Chain 1
627–856（230 aa）
Chain 2
76–331（256 aa）
Chain 3
332–567（236 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.80 Å |
| 8PNF HRV B14 virion proteins Deposited 2023-06-30 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–RNA Homooligomer；Protein × 240 PDB declaration: 300-meric |
Chain 1
574–856（283 aa）
Chain 2
76–331（256 aa）
Chain 3
332–567（236 aa）
Chain 4
23–69（47 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.90 Å |
| 9LGP Crystal structure of the HRV B14 3C protease in complex with AG7404 Deposited 2025-01-10 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1538–1719（182 aa）
|
Not recorded | XNV ethyl (4R)-4-({(2S)-2-[3-{[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino}-2-oxopyridin-1(2H)-yl]pent-4-ynoyl}amino)-5-[(3S)-2-oxopyrrolidin-3-yl]pentanoate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；289.15 K；0.1 M Tris-HCl, 0.8 M Lithium chloride, 36%(w/v) PEG 4000
|
Resolution 2.11 Å R-free 0.267 |
| 9LGP Crystal structure of the HRV B14 3C protease in complex with AG7404 Deposited 2025-01-10 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1538–1719（182 aa）
|
Not recorded | XNV ethyl (4R)-4-({(2S)-2-[3-{[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino}-2-oxopyridin-1(2H)-yl]pent-4-ynoyl}amino)-5-[(3S)-2-oxopyrrolidin-3-yl]pentanoate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；289.15 K；0.1 M Tris-HCl, 0.8 M Lithium chloride, 36%(w/v) PEG 4000
|
Resolution 2.11 Å R-free 0.267 |
| 9LGP Crystal structure of the HRV B14 3C protease in complex with AG7404 Deposited 2025-01-10 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
1538–1719（182 aa）
|
Not recorded | XNV ethyl (4R)-4-({(2S)-2-[3-{[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino}-2-oxopyridin-1(2H)-yl]pent-4-ynoyl}amino)-5-[(3S)-2-oxopyrrolidin-3-yl]pentanoate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；289.15 K；0.1 M Tris-HCl, 0.8 M Lithium chloride, 36%(w/v) PEG 4000
|
Resolution 2.11 Å R-free 0.267 |
| 9LGP Crystal structure of the HRV B14 3C protease in complex with AG7404 Deposited 2025-01-10 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain D
1538–1719（182 aa）
|
Not recorded | XNV ethyl (4R)-4-({(2S)-2-[3-{[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino}-2-oxopyridin-1(2H)-yl]pent-4-ynoyl}amino)-5-[(3S)-2-oxopyrrolidin-3-yl]pentanoate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；289.15 K；0.1 M Tris-HCl, 0.8 M Lithium chloride, 36%(w/v) PEG 4000
|
Resolution 2.11 Å R-free 0.267 |
| 9U5P HRV14 3C in complex with single chain antibody YDF and cloverleafRNA-dimer conformation Deposited 2025-03-21 | Different construct Different mutation/modification Different oligomeric state Different structure-quality metrics | Assembly 1 Protein–RNA Heteromer；Protein × 6 PDB declaration: heptameric |
Chain A
1539–1718（180 aa）
Chain O
1539–1718（180 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.96 Å |
| 9U5Q HRV14 3C in complex with single chain antibody YDF and cloverleafRNA-conformation1 Deposited 2025-03-21 | Different structure-quality metrics | Assembly 1 Protein–RNA Heteromer；Protein × 3 PDB declaration: tetrameric |
Chain A
1539–1718（180 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.35 Å |
| 9U5R HRV14 3C in complex with single chain antibody YDF and cloverleafRNA-conformation 2 Deposited 2025-03-21 | Different structure-quality metrics | Assembly 1 Protein–RNA Heteromer；Protein × 3 PDB declaration: tetrameric |
Chain O
1539–1718（180 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.59 Å |
| 9URM HRV14 3C in complex with single chain antibody YDF and cloverleafRNA-conformation1 splitRNA Deposited 2025-04-30 | Different structure-quality metrics | Assembly 1 Protein–RNA Heteromer；Protein × 3 PDB declaration: tetrameric |
Chain A
1539–1718（180 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.24 Å |
| 9VMD HRV14 3C in complex with single chain antibody YDF and cloverleafRNA-conformation2 splitRNA Deposited 2025-06-27 | Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–RNA Heteromer；Protein × 3 PDB declaration: tetrameric |
Chain O
1539–1718（180 aa）
|
Not recorded | No recorded non-water small molecule | ELECTRON MICROSCOPY mmCIF provides none of the parsed conditions | Resolution 4.38 Å |
| 9WB4 HRV14 3C in complex with single chain antibody YDF and cloverleafRNA-conformation1-composite-2 Deposited 2025-08-13 | Different structure-quality metrics | Assembly 1 Protein–RNA Heteromer；Protein × 3 PDB declaration: tetrameric |
Chain A
1539–1718（180 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.32 Å |
58 other PDB entries and 240 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | POLG_HRV14 |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A； PDBConstruct 1–180； UniProt 1539–1718 |
